BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 10072106)

  • 1. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.
    Harris GM; Stendt CL; Vollenhoven BJ; Gan TE; Tipping PG
    Am J Hematol; 1999 Mar; 60(3):175-80. PubMed ID: 10072106
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives.
    Norris LA; Bonnar J
    Br J Obstet Gynaecol; 1996 Mar; 103(3):261-7. PubMed ID: 8630312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on oral contraceptive-induced changes in blood coagulation and fibrinolysis and the estrogen effect on endothelial cells.
    Quehenberger P; Kapiotis S; Pärtan C; Schneider B; Wenzel R; Gaiger A; Speiser W
    Ann Hematol; 1993 Jul; 67(1):33-6. PubMed ID: 8392873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemostatic changes and the oral contraceptive pill.
    Norris LA; Bonnar J
    Baillieres Clin Obstet Gynaecol; 1997 Sep; 11(3):545-64. PubMed ID: 9488791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of low-dose oral triphasic contraceptives on blood viscosity, coagulation and lipid metabolism.
    Coata G; Ventura F; Lombardini R; Ciuffetti G; Cosmi EV; Di Renzo GC
    Contraception; 1995 Sep; 52(3):151-7. PubMed ID: 7587186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coagulation studies in women using combination type of oral contraceptives.
    Sharma S; Sharma M; Soni IJ; Gupta A; Jain R
    J Obstet Gynaecol India; 1983 Aug; 33(4):519-24. PubMed ID: 12339832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based study of risk of venous thromboembolism associated with various oral contraceptives.
    Farmer RD; Lawrenson RA; Thompson CR; Kennedy JG; Hambleton IR
    Lancet; 1997 Jan; 349(9045):83-8. PubMed ID: 8996419
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor VII activation and oral contraceptives.
    Plu-Bureau G; Scarabin PY; Bara L; Malmejac A; Guize L; Samama M
    Thromb Res; 1993 May; 70(3):275-80. PubMed ID: 8327993
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contraceptive choices in women with coagulation disorders.
    Comp PC; Zacur HA
    Am J Obstet Gynecol; 1993 Jun; 168(6 Pt 2):1990-3. PubMed ID: 8512043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical aspects of the relationship between oral contraceptives and abnormalities of the hemostatic system: relation to the development of cardiovascular disease.
    Kelleher CC
    Am J Obstet Gynecol; 1990 Jul; 163(1 Pt 2):392-5. PubMed ID: 2196811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraception and coagulation.
    Notelovitz M
    Clin Obstet Gynecol; 1985 Mar; 28(1):73-83. PubMed ID: 3987135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Büller HR; Vandenbroucke JP
    Lancet; 1995 Dec; 346(8990):1593-6. PubMed ID: 7500751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in haemostatic variables induced by oral contraceptives containing 50 micrograms or 30 micrograms oestrogen: absence of dose-dependent effect on PAI-1 activity.
    Scarabin PY; Plu-Bureau G; Zitoun D; Bara L; Guize L; Samama MM
    Thromb Haemost; 1995 Sep; 74(3):928-32. PubMed ID: 8571323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An epidemiological study of the haemostatic and other effects of oral contraceptives.
    Meade TW; Brozović M; Chakrabarth R; Howarth DJ; North WR; Stirling Y
    Br J Haematol; 1976 Nov; 34(3):353-64. PubMed ID: 990177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostasis profile and lipid metabolism with long-interval use of a desogestrel-containing oral contraceptive.
    Cachrimanidou AC; Hellberg D; Nilsson S; von Schoulz B; Crona N; Siegbahn A
    Contraception; 1994 Aug; 50(2):153-65. PubMed ID: 7956214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of oral contraceptives on blood coagulation. A review.
    Beller FK; Ebert C
    Obstet Gynecol Surv; 1985 Jul; 40(7):425-36. PubMed ID: 3895067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on hemostasis after two-year use of low dose combined oral contraceptives with gestodene or levonorgestrel.
    Prasad RN; Koh SC; Viegas OA; Ratnam SS
    Clin Appl Thromb Hemost; 1999 Jan; 5(1):60-70. PubMed ID: 10725985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.